Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer

Kotoe Takayoshi, Keita Uchino, Masahiro Nakano, Koji Ikejiri, Eishi Baba

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Patients with advanced gastric cancer (AGC) often suffer weight loss, which can be used to predict prognosis. Few reports have assessed the correlation between weight loss during chemotherapy and survival in patients with AGC. Methods: Fifty-three patients with histologically proven AGC, who started systemic chemotherapy from September 2010 to March 2014, were retrospectively examined for body weight, inflammatory status, and survival. Correlation analyses were performed between weight change and survival. Correlations between weight loss and the patient characteristics were analyzed by stepwise multiple regression analyses. Results: The mean age of the patients was 64.4 years; 64% of the patients were males. Initial chemotherapy included fluoropyrimidine plus cisplatin (62%), fluoropyrimidine alone (26%), and other medications (12%); 72% of the patients exhibited weight loss during the initial therapy. Poorer mean overall survival and mean progression-free survival were observed in patients with weight loss of higher-than-average values than in those with weight loss of lower-than-average values. Serum C-reactive protein levels were significantly correlated with weight loss. Conclusions: Weight loss during initial chemotherapy for AGC may predict survival. Systemic inflammation is suggested to be associated with weight loss.

Original languageEnglish
Pages (from-to)408-415
Number of pages8
JournalNutrition and Cancer
Volume69
Issue number3
DOIs
Publication statusPublished - Apr 3 2017

Fingerprint

Stomach Neoplasms
Weight Loss
Drug Therapy
Survival
C-Reactive Protein
Cisplatin
Disease-Free Survival
Blood Proteins
Body Weight
Regression Analysis
Inflammation
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Oncology
  • Nutrition and Dietetics
  • Cancer Research

Cite this

Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer. / Takayoshi, Kotoe; Uchino, Keita; Nakano, Masahiro; Ikejiri, Koji; Baba, Eishi.

In: Nutrition and Cancer, Vol. 69, No. 3, 03.04.2017, p. 408-415.

Research output: Contribution to journalArticle

Takayoshi, Kotoe ; Uchino, Keita ; Nakano, Masahiro ; Ikejiri, Koji ; Baba, Eishi. / Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer. In: Nutrition and Cancer. 2017 ; Vol. 69, No. 3. pp. 408-415.
@article{ab0036b8b5104f729b271c6fff27d341,
title = "Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer",
abstract = "Background: Patients with advanced gastric cancer (AGC) often suffer weight loss, which can be used to predict prognosis. Few reports have assessed the correlation between weight loss during chemotherapy and survival in patients with AGC. Methods: Fifty-three patients with histologically proven AGC, who started systemic chemotherapy from September 2010 to March 2014, were retrospectively examined for body weight, inflammatory status, and survival. Correlation analyses were performed between weight change and survival. Correlations between weight loss and the patient characteristics were analyzed by stepwise multiple regression analyses. Results: The mean age of the patients was 64.4 years; 64{\%} of the patients were males. Initial chemotherapy included fluoropyrimidine plus cisplatin (62{\%}), fluoropyrimidine alone (26{\%}), and other medications (12{\%}); 72{\%} of the patients exhibited weight loss during the initial therapy. Poorer mean overall survival and mean progression-free survival were observed in patients with weight loss of higher-than-average values than in those with weight loss of lower-than-average values. Serum C-reactive protein levels were significantly correlated with weight loss. Conclusions: Weight loss during initial chemotherapy for AGC may predict survival. Systemic inflammation is suggested to be associated with weight loss.",
author = "Kotoe Takayoshi and Keita Uchino and Masahiro Nakano and Koji Ikejiri and Eishi Baba",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/01635581.2017.1267774",
language = "English",
volume = "69",
pages = "408--415",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Routledge",
number = "3",

}

TY - JOUR

T1 - Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer

AU - Takayoshi, Kotoe

AU - Uchino, Keita

AU - Nakano, Masahiro

AU - Ikejiri, Koji

AU - Baba, Eishi

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Background: Patients with advanced gastric cancer (AGC) often suffer weight loss, which can be used to predict prognosis. Few reports have assessed the correlation between weight loss during chemotherapy and survival in patients with AGC. Methods: Fifty-three patients with histologically proven AGC, who started systemic chemotherapy from September 2010 to March 2014, were retrospectively examined for body weight, inflammatory status, and survival. Correlation analyses were performed between weight change and survival. Correlations between weight loss and the patient characteristics were analyzed by stepwise multiple regression analyses. Results: The mean age of the patients was 64.4 years; 64% of the patients were males. Initial chemotherapy included fluoropyrimidine plus cisplatin (62%), fluoropyrimidine alone (26%), and other medications (12%); 72% of the patients exhibited weight loss during the initial therapy. Poorer mean overall survival and mean progression-free survival were observed in patients with weight loss of higher-than-average values than in those with weight loss of lower-than-average values. Serum C-reactive protein levels were significantly correlated with weight loss. Conclusions: Weight loss during initial chemotherapy for AGC may predict survival. Systemic inflammation is suggested to be associated with weight loss.

AB - Background: Patients with advanced gastric cancer (AGC) often suffer weight loss, which can be used to predict prognosis. Few reports have assessed the correlation between weight loss during chemotherapy and survival in patients with AGC. Methods: Fifty-three patients with histologically proven AGC, who started systemic chemotherapy from September 2010 to March 2014, were retrospectively examined for body weight, inflammatory status, and survival. Correlation analyses were performed between weight change and survival. Correlations between weight loss and the patient characteristics were analyzed by stepwise multiple regression analyses. Results: The mean age of the patients was 64.4 years; 64% of the patients were males. Initial chemotherapy included fluoropyrimidine plus cisplatin (62%), fluoropyrimidine alone (26%), and other medications (12%); 72% of the patients exhibited weight loss during the initial therapy. Poorer mean overall survival and mean progression-free survival were observed in patients with weight loss of higher-than-average values than in those with weight loss of lower-than-average values. Serum C-reactive protein levels were significantly correlated with weight loss. Conclusions: Weight loss during initial chemotherapy for AGC may predict survival. Systemic inflammation is suggested to be associated with weight loss.

UR - http://www.scopus.com/inward/record.url?scp=85010006566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010006566&partnerID=8YFLogxK

U2 - 10.1080/01635581.2017.1267774

DO - 10.1080/01635581.2017.1267774

M3 - Article

C2 - 28102709

AN - SCOPUS:85010006566

VL - 69

SP - 408

EP - 415

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 3

ER -